Loading
NASDAQHealthcareBiotechnology
Latest quote
$12.915
−$0.045 · -0.35%
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Previous close
$12.915
−$0.045 · -0.35%
Pre-market
$12.8146
−$0.1004 · -0.78%
Oct 8, 7:24 AM ET
Regular session · ET · Market data may be delayed.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Day range
Current $12.915
52-week range
Current $12.915
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
77
Undervalued
Sentiment
64
Bullish
Risk
48
Elevated Risk
Momentum
66
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Day range
Current $12.915
52-week range
Current $12.915
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 26, 2013 | 1:100 | — | — |
Stock split | May 26, 2010 | 23,999:1,000 | — | — |
Effective Sep 26, 2013
1:100
Effective May 26, 2010
23,999:1,000
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI152.72M1.48%10.08B USD0.35%$150.23-0.44%
iShares Russell 2000 ETFIWM134.49M0.17%78.56B USD0.19%$277.7-1.29%
Vanguard Morningstar Total Stock Market ETFVTI110.37M0.00%2.3T USD0.03%$381.03-0.40%
Vanguard Morningstar Small-Cap ETFVB39.85M0.02%185.3B USD0.03%$286.98-1.41%
iShares Biotechnology ETFIBB38.57M0.37%10.4B USD0.44%$203.34+0.12%
Vanguard Extended Market ETFVXF35.64M0.04%95.4B USD0.05%$233.49-1.56%
Dimensional - US Small Cap ETFDFAS27.62M0.08%33.66B USD0.31%$77.92-1.38%
Schwab U.S. Small-Cap ETFSCHA26.62M0.12%22.01B USD0.03%$32.61-1.47%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
